Century Therapeutics Inc

Century Therapeutics announced that its abstracts were accepted for oral presentations at two upcoming scientific congresses, both highlighting CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes. The presentations are scheduled for the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan, Italy, from September 28 to October 2, 2026, and the Breakthrough T1D Clinical & Research Congress 2026 in Philadelphia, Pennsylvania, from October 9 to 11, 2026. CNTY-813 is engineered with Allo-Evasion 5.0 to enable durable engraftment without chronic systemic immunosuppression, and the company is targeting an IND submission in the fourth quarter of 2026. On June 9, Century Therapeutics presented new preclinical data for CNTY-813 at the American Diabetes Association Scientific Sessions, showing durable glucose control for over eight months and maintained insulin secretion under allogeneic immune pressure without immunosuppression. CEO Brent Pfeiffenberger stated the data advance the case for a potentially functional cure for type 1 diabetes, with initial clinical data anticipated in the second half of 2027.

The cutaneous lupus erythematosus market across the seven major markets was valued at USD 650 million in 2025 and is projected to expand at a compound annual growth rate of 8% during the 2026 to 2036 forecast period, according to a new report from DelveInsight. The United States accounted for the largest share of the market in 2025, representing around 60% of total diagnosed prevalent cases in the seven major markets, which also include the EU4 countries Germany, France, Italy, and Spain, the United Kingdom, and Japan. Antimalarials contributed over 50% of total annual revenue in 2025 across these markets. Growth is being driven by rising autoimmune disease prevalence, improved diagnosis, and a pipeline of emerging targeted therapies such as Litifilimab from Biogen, Daxdilimab from Amgen and Horizon Therapeutics, SOTYKTU from Bristol Myers Squibb, IMVT-1402 from Immunovant Sciences, VENT-03 from Ventus Therapeutics, CNTY-101 from Century Therapeutics, Anifrolumab from AstraZeneca, and Enpatoran from Merck. Biogen's Litifilimab received breakthrough therapy designation from the US FDA in January 2026 and reported positive Phase II results in March 2026, while Amgen announced positive Phase II results for Daxdilimab in discoid lupus erythematosus in 2026 and is considering advancing it to Phase III.